No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RGNX240719P22500
- 6.50
- 0.000.00%
15min DelayClose Feb 9 13:55 ET
0.00High0.00Low
0.00Open6.50Pre Close0 Volume2 Open Interest22.50Strike Price0.00Turnover0.00%IV-25.29%PremiumJul 19, 2024Expiry Date9.73Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.34Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Regenxbio(RGNX.US) Director Sells US$112.69K in Common Stock
$Regenxbio(RGNX.US)$ Director KARABELAS ARGERIS N sold 10,000 shares of common stock on Jul 1, 2024 at an average price of $11.2691 for a total value of $112.69K.Source: Announcement What is statement
Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.Oppe
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Comments
$Regenxbio(RGNX.US$ SELL SELL SELL NOW EASY MONEY AND ENJOIN YOURS TAKE BREAK TOMORROW 💰💰💰😋😋😋🤩🤩🤩
Investors' pessimism about the company's revenue prospects may be causing the low P/S ratio. The company's forecast growth is lower than the wider industry, which could be contributing to the depressed P/S. It's hard to see the share price rising strongly in the near future given these circumstances.
$Regenxbio(RGNX.US$ on 07 Feb will provide an interim clinical study update of RHX121 for treatment of neuropathic mucopolysaccharaidosis.
Read more